CorMedix (CRMD) Cash & Current Investments (2010 - 2026)

CorMedix has reported Cash & Current Investments for 16 years, with the latest figure at $155.2 million in Q4 2025.

• Quarterly Cash & Current Investments rose 200.27% year-over-year to $155.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $155.2 million (up 200.27% YoY) and the FY2025 annual result came in at $155.2 million, up 200.27% from the prior year.
• Cash & Current Investments improved to $155.2 million in Q4 2025 per CRMD's latest filing, from $56.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $190.7 million in Q2 2025 and troughed at $22.7 million in Q1 2022.
• A 5-year average of $65.9 million and a median of $57.6 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2021 and 2022: Cash & Current Investments surged 42266.88% in 2021, then slumped 72.03% in 2022.
• Over 5 years, Cash & Current Investments stood at $65.5 million in 2021, then plunged by 33.9% to $43.3 million in 2022, then surged by 75.7% to $76.0 million in 2023, then tumbled by 32.02% to $51.7 million in 2024, then soared by 200.27% to $155.2 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $155.2 million, $56.6 million, and $190.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.